Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series

BACKGROUND: Tocilizumab is a monoclonal antibody directed against the interleukin-6 receptor, which is approved for the treatment of moderate-to-severe rheumatoid arthritis. Authors have found that it prevents lung and subcutaneous nodulosis in patients with rheumatoid arthritis but, to the best of...

Descripción completa

Detalles Bibliográficos
Autores principales: Talotta, Rossella, Atzeni, Fabiola, Batticciotto, Alberto, Ditto, Maria Chiara, Gerardi, Maria Chiara, Sarzi-Puttini, Piercarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985057/
https://www.ncbi.nlm.nih.gov/pubmed/29859543
http://dx.doi.org/10.1186/s13256-018-1687-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985057/
https://www.ncbi.nlm.nih.gov/pubmed/29859543
http://dx.doi.org/10.1186/s13256-018-1687-y

Ejemplares similares